DALLAS / Aug 10, 2023 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) today announced that its Board of Directors has elected Chief Executive Officer, Saum Sutaria, M.D., to assume the additional position of Chairman, effective immediately. Sutaria succeeds Senator J. Robert Kerrey, who will transition to Lead Director of the Board, a role he previously held from 2017- 2022.
Sutaria has served as Tenet Healthcare’s CEO since September 2021 and a member of the Board of Directors since 2020. Previously, he served as the Company’s Chief Operating Officer.
“The appointment of Saum to Chairman is a testament to his steadfast leadership and commitment to Tenet Healthcare,” said Senator J. Robert Kerrey, Lead Director. “The Board looks forward to working closely with him in this new capacity to continue to create value for all our stakeholders.”
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 475 ambulatory surgery centers and surgical hospitals. We also operate 61 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$128.82 |
Daily Change: | -0.89 -0.69 |
Daily Volume: | 16,288 |
Market Cap: | US$12.250B |
October 29, 2024 July 24, 2024 April 30, 2024 February 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB